Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 5/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 2/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL1176577 | 1.00 | PNP (0.62) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL28189108 | 0.98 | PNP (0.61) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL27871419 | 0.98 | PNP (0.61) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL28385604 | 0.98 | PNP (0.61) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL27833745 | 0.98 | PNP (0.61) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL28849539 | 0.95 | PNP (0.57) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL10532086 | 0.92 | PNP (0.54) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL28849538 | 0.92 | PNP (0.54) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL5977650 | 0.90 | PNP (0.57) | PNPALDH1A1XDHHPGDUSP2 | |
| Thioguanine SCHEMBL17515061 | 0.90 | PNP (0.57) | PNPALDH1A1XDHHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 156217 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-0038357-A1 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS | University of Illinois Foundation (US) | 1981-10-28 | — | — | EP | claimed |
| EP-0038541-A1 | Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same | MERCK & CO. INC. (US) | 1981-10-28 | — | — | EP | claimed |
| US-4291024-A | ANTICANCER AGENTS | UNIVERSITY OF RHODE ISLAND | 1981-09-22 | — | — | US | claimed |
| EP-0033341-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | Research Corporation (US) | 1981-08-12 | — | — | EP | claimed |
| US-4283394-A | ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | claimed |
| WO-1981001145-A1 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS | UNIV ILLINOIS (US) | 1981-04-30 | — | — | WO | claimed |
| WO-1981000410-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | RESEARCH CORP (US) | 1981-02-19 | — | — | WO | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |
| US-4147767-A | CROSSLINKED WITH FORMALDEHYDE OR GLUTARALDEHYDE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1979-04-03 | — | — | US | claimed |
| US-4066510-A | ASSAY FOR MUTAGENESIS IN DIPLOID HUMAN LYMPHOBLASTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1978-01-03 | — | — | US | claimed |